Transchymal-AD are stromal originated mesenchymal stem cells (MSCs) composed platform, that can differentiate in vitro into a variety of cell types including osteoblasts (bone), chondrocytes (cartilage), adipocytes (fat), myocytes (muscle). This platform has undifferentiated cells, and because they are able to self-renew have a high proliferative capacity. Transchymal-AD is harvested from normal (non-diabetic) adult lipoaspirates discarded during elective surgical liposuction. These cells are characterised by the expression of cell-surface markers: CD90, CD105, and CD73, and by the absence of CD34, CD45, and HLA-DR surface molecules; they are plastic adherent when maintained in standard culture conditions.
Transchymal-AD cells are expanded in culture and configured in the packaging format.
Care is taken to ensure the safety of the donor and the integrity of collected cells, and all cell collection and handling procedures are compliant with government and Institutional Ethics Committee (IEC). Donors are tested for infection by HIV-1, HIV-2, HBV, HCV, Mycoplasma, Bacteria, Yeast and Fungi before collection. Cells are processed batch wise to be bioburden free.
Configured Transchymal-AD cell systems have applications suitable for developing humanised 3D biomodels that are ex vivo systems in the evaluation of test materials for human application and compatibility (chart).
Disclaimer: Product for in vitro research use only. Not approved for diagnostic, therapeutic, or clinical applications. Not approved for human or veterinary use in vivo.